JUNS Jupiter Neurosciences, Inc.
USHealthcareAs of 2026-07-09 16:00
Why JUNS matters now
Jupiter Neurosciences, Inc. (JUNS) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.20 with +1.66% on the session and $7.1M in market capitalization; recent performance reads 1-month -25.63% and YTD -76.67%.
The latest financial table shown here is Q1 2026, with revenue of $18.7K, net income of $-2.1M, and EPS of $-0.06. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -66.8%.
The latest indexable market news headline is "Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Brady Allison W filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-3.01
P/S
213.89
EV/EBITDA
-1.24
DCF Value
$-0.04
FCF Yield
-66.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.2%
Operating Margin
-23075.8%
Net Margin
-22690.8%
ROE
1140.9%
ROA
-232.4%
ROIC
-455.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $18.7K | $-2.1M | $-0.06 |
| Q4 2025 | $21.8K | $-2.6M | $-0.07 |
| FY 2025 | $21.8K | $-8.6M | $-0.25 |
| Q3 2025 | $0.00 | $-2.3M | $-0.07 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.69
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.